Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tanvex BioPharma's Total Assets for the quarter that ended in Mar. 2026 was NT$7,637.9 Mil.
During the past 12 months, Tanvex BioPharma's average Total Assets Growth Rate was 9.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 39.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 16.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.60% per year.
During the past 13 years, Tanvex BioPharma's highest 3-Year average Total Assets Growth Rate was 63.20%. The lowest was -1.80%. And the median was 19.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Tanvex BioPharma's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Tanvex BioPharma Total Assets Related Terms
Tanvex BioPharma Total Assets Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Tanvex BioPharma's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Total Assets of NT$7,637.9 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Total Assets too high?
Tanvex BioPharma's current Total Assets is NT$7,637.9 Mil. Overall, Tanvex BioPharma has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Total Assets compare to VRTX and REGN?
Tanvex BioPharma's Total Assets of NT$7,637.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Total Assets is NT$7,637.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Total Assets of NT$7,637.9 Mil. The current Total Assets is NT$7,637.9 Mil. Tanvex BioPharma's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Total Assets is NT$7,637.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
47GF Score
Get the complete analysis for TPE:6541
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
